Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Licensing Agreements 22
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Genentech to Enter into Licensing Agreement with Hanmi Pharma 23
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 24
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 25
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 26
Kinex Pharma Expands Licensing Agreement with Hanmi Pharma for Orascovery Program 27
Hanmi Pharma Enters into Licensing Agreement with Kinex Pharma for KX01 28
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 29
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 30
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 31
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 32
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 33
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 34
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 36
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 37
Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 38
Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 40
Acquisition 41
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 41
Hanmi Pharmaceuticals Co Ltd – Key Competitors 42
Hanmi Pharmaceuticals Co Ltd – Key Employees 43
Hanmi Pharmaceuticals Co Ltd – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
Feb 05, 2016: Hanmi Pharmaceutical’s sales reach record high of W1.3175 trillion 45
Product News 46
06/17/2016: Hanmi Presented the Research Results of HM-12525A Long Acting Diabetes-Obesity Medicine at American Diabetes Association meeting 46
06/02/2016: Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib 47
03/31/2017: Spectrum Pharmaceuticals Announces Presentation of Abstract on ROLONTIS (eflapegrastim) at the AACR 49
Product Approvals 50
May 17, 2016: South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713) 50
Jan 25, 2016: Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel 51
Clinical Trials 52
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor 52
Apr 04, 2017: Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting 53
Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations 54
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium 55
Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer 56
Dec 05, 2016: Spectrum Pharmaceuticals Highlights Four Abstracts on ROLONTIS (eflapegrastim) at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016 57
Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016 59
Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016 60
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO 61
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug Olmutinib at ASCO 62
Jun 05, 2016: New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores clinical potential of Boehringer Ingelheim’s next generation lung cancer compound 63
Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor 64
Jan 29, 2016: Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Hanmi Pharmaceuticals Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Genentech to Enter into Licensing Agreement with Hanmi Pharma 23
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 24
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 25
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 26
Kinex Pharma Expands Licensing Agreement with Hanmi Pharma for Orascovery Program 27
Hanmi Pharma Enters into Licensing Agreement with Kinex Pharma for KX01 28
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 29
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 30
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 31
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 32
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 33
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 34
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 36
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 37
Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 38
Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 40
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 41
Hanmi Pharmaceuticals Co Ltd, Key Competitors 42
Hanmi Pharmaceuticals Co Ltd, Key Employees 43
Hanmi Pharmaceuticals Co Ltd, Other Locations 44
Hanmi Pharmaceuticals Co Ltd, Subsidiaries 44